26th week of 2012 patent applcation highlights part 45 |
Patent application number | Title | Published |
20120164083 | Sweetness Enhancers Including Rebaudioside A or D - The present invention is directed to the use of rebaudioside A or rebaudioside D in combination with one or more compounds of Formula (I), or a stereoisomer thereof, wherein R | 2012-06-28 |
20120164084 | COMPOSITION AND METHOD TO FLAVOR ORAL CARE COMPOSITIONS CONTAINING A CHLORINE DIOXIDE SOURCE - A flavored oral care composition and method of making same for preventing and/or treating bacterial, fungal or inflammatory diseases and conditions of the oral cavity may be in the form of a rinse, spray, or the like, and free of glycerin and free of castor oil and castor oil derivatives, incorporates a chlorine dioxide source, a phosphate buffer, a flavoring system containing a polyoxyethylene sorbitan ester (emulsifier/suspender) and flavoring agent, a sweetener and water. With the addition of a fluoride ion source, the composition may be used as an anticaries agent. | 2012-06-28 |
20120164085 | Flavour Compositions - A flavor composition which includes as, at least 8% of its total weight, (a) at least 0.5% by weight of a peppermint oil containing 1-isopropylidene-4-methyl-2-cyclohexanone in an amount from 1% to 4% by weight, 5-methyl-2-(1-methylethyl)-1-cyclohexanone in an amount from 8% to 13% by weight and less than 0.5% by weight of eucalyptol; and a spearmint oil containing less than 70% by weight of carvone and at least 14% by weight of limonene; or mixtures thereof; and (b) at least 0.5% by weight of two or more of the following: decanol, octanal, allyl hexanoate, anethole, anised rectified, basil oil, benzyl butyrate, camomile oil, cinnamic aldehyde, cis-3-hexenyl acetate, citral natural, citronella ceylon, ethyl heptanoate, eugenol, fennel sweet, geranyl acetate, ionone alpha, lime, orange flavour, para cresyl methyl ether and pinene alpha. The compositions are useful in reducing oral malodors. | 2012-06-28 |
20120164086 | Production Method Of O/W Emulsion Composition - The present invention provides a production method that can easily produce an O/W emulsion composition without using a special cooling apparatus and be economical. The production method of an O/W emulsion composition comprising: emulsifying, at 70° C. or higher, an oil phase with a portion of a water phase to prepare an emulsified part, wherein the oil phase comprises (A) a nonionic surfactant, (B) a linear higher alcohol that has 16 or more carbon atoms and can form an α-gel in water with the nonionic surfactant, and (C) an oil component, and the water phase comprises (D) water; mixing the remaining main water phase at 10 to 35° C. with the emulsified part while being stirred, to cool the emulsified part with continuous stirring to the lower temperature limit, or lower, of a temperature range wherein the oil phase forms an α-gel in the water phase; and then stopping the stirring. | 2012-06-28 |
20120164087 | Human Serum Albumin-Based Topical Ointment for Treatment of Acne, Psoriasis, Egfr-Induced Toxicity, Premature Skin Aging and Other Skin Conditions - Dermatological compositions and method for treating psoriasis, eczema, acne and like skin conditions for sanitization pharmaceutical compounding and protection of the skin from extreme environmental conditions are provided which contain serum albumin in an amount effective to treat, reduce the symptoms and improve the appearance of affected skin due to psoriasis, eczema, and acne and like conditions, enhance the delivery performance or stability of pharmaceutical compounding bases, protect the skin from the environment and premature aging, and to lubricate and/or promote the healing of eye after surgical or accidental trauma, when combined with a suitable topical ointment, antibacterial or dermatological agent, pharmaceutical compounding ointment or bases, vehicle, carrier or excipient. The albumin compositions may be in any suitable form for treating skin, such as a cream, oil, lotion, gel, gel-based ointment, and the like. The serum albumin compositions are preferably prepared using recombinant human serum albumin, a truncated version or fragment thereof. | 2012-06-28 |
20120164088 | COSMETIC COMPOSITION CONTAINING ENZYME AND AMINO ACID - The present invention relates to a skin cosmetic composition containing enzyme and amino acid. More particularly, the skin cosmetic composition according to the invention contains enzyme and amino acid, and thus safely improves stratum corneum thickening resulting from the progression of skin aging, improves skin drying occurring during keratin removal, and shows excellent skin moisturizing and whitening effects. | 2012-06-28 |
20120164089 | ANTHOCYANIN PIGMENT/DYE COMPOSITIONS AND SOLUTIONS THROUGH CORN EXTRACTION - Anthocyanin pigments/dyes are extracted from natural, hybrid or inbred corn kernels by adding corn kernels with less than 5% by weight of corn kernels comprising broken kernels to an aqueous medium to form an aqueous-corn medium. The corn kernels have in excess of 0.1 mg of anthocyanin pigment/dye per gram of corn kernel therein. The anthocyanin pigment/dye in the corn kernels has greater than 40% by weight of anthocyanin as an acid or acylated form of the anthocyanin. The aqueous corn medium is agitated at a temperature above 35° C. The solid corn kernels are separated from the aqueous corn medium to form an extract of anthocyanin in aqueous medium having less than 1.0% solids therein before concentration or purification steps are performed on the extract. | 2012-06-28 |
20120164090 | CONTINUOUS MANUFACTURING SYSTEM - A continuous system for manufacturing a composition that contains an active ingredient that includes a base manufacturing portion and an addition portion. The system can manufacture compositions having different levels of the active ingredient. A base is formed that contains a first level of the active ingredient that is desired for any composition to be manufactured. The addition portion can be used to add more of the materials for the composition to lower the level of the active ingredient, or more active ingredient can be added to increase the level of the active ingredient. The system is controlled by a sensor that measures an amount of associated material that is associated with the active ingredient. This is useful when the active ingredient is not detectable by the sensor. | 2012-06-28 |
20120164091 | Long Wearing Powder-Based Cosmetic Compositions - There is provided a long-wearing powder-based cosmetic or personal care composition. The composition comprises a thermoplastic elastomer, such as a styrene-isobutylene-styrene (SIBS) triblock copolymer, a non-volatile oil, and a film forming polymer comprising a polypropylene glycol (PPG) backbone. | 2012-06-28 |
20120164092 | Hair Styling Cosmetic Composition - To provide a hair styling cosmetic composition which is excellent in hair styling property and hair restyling property, even though being water-based and having a low viscosity, and is excellent in non-stickiness, smoothness, and light finish of the hair. A hair styling cosmetic composition comprising (a) a polyalkylene glycol polymer being solid at room temperature (25° C.), (b) one or more substances being liquid at room temperature (25° C.) selected from among (b-1) a di- to tetra-alcohol, (b-2) an alkylene oxide addition polymer of a mono- to tetra-alcohol or a mono- to tri-carboxylic acid, and (b-3) a polyalkylene glycol polymer, (c) a film-forming polymer, and (d) a sugar alcohol, wherein the ratio of component (a) to component (b) is from 1/0.2 to 1/10 (by mass), the ratio of component (b) to component (c) is from 1/0.1 to 1/1 (by mass), the total content of components (a) to (d) is at least 10% by mass, and the viscosity of the system is at most 10,000 mPa·s (at 25° C. with B-type viscometer). | 2012-06-28 |
20120164093 | Use of Glutamide Stabilizers - Fluids are provided which resist phase separation by inclusion of a stabilizing amount of a glutamic acid derivative in the presence of ethanol. The fluids comprise an aqueous discontinuous phase, a silicone oil containing continuous phase, a glutamic acid derivative such as dibutyl ethylhexanoyl glutamide, and ethanol. The fluids may be prepared without heating to solubilize the glutamic acid derivative | 2012-06-28 |
20120164094 | Production Method Of High-Viscosity O/W Cream - The present invention provides a simple and economical production method, without using a large amount of thickeners, of a high-viscosity O/W cream. The production method comprising: emulsifying, at 70° C. or higher, an oil phase with a water phase to prepare an O/W emulsified part, wherein the oil phase comprises (A) a nonionic surfactant, (B) a linear higher alcohol that has 16 or more carbon atoms and can form an α-gel in water with (A), and (C) an oil component, and the water phase comprises (D) water; cooling the emulsified part while being stirred; and stopping the stirring at the peak temperature or higher in a temperature range wherein the oil phase forms an α-gel in the water phase, but lower than 70° C. The peak temperature is the exothermic peak measured by DSC of the emulsified part. The viscosity of the O/W cream measured with a B-type viscometer at 30° C. is preferably 8,000 mPa·s or higher. | 2012-06-28 |
20120164095 | BETA-AMINO ESTER COMPOUNDS AND USES THEREOF - Hair treatment compositions are disclosed comprising a β-amino ester compound in a cosmetically acceptable vehicle, such as a spray or cream. In embodiments, the compounds include a polybutadiene moiety. Methods of treating hair with the compositions to impart volume, texture and definition are also disclosed. | 2012-06-28 |
20120164096 | LIQUID SHAVING PREPARATION - The invention relates to a preparation for topical use, consisting in a solution of cosmetic products that allows their use as a shaving product. The invention comprises the use of deodorised alcohol at a concentration by weight equal to or less than 60%. The use of deodorised alcohol allows the use of perfume aromas at low concentrations or not at all, which does not therefore condition the user in their use of their own personal perfume, allowing them to combine the shaving preparation with the fragrances of their choice, provided by other products. The use of an alcohol concentration of less than 60% by weight involves a reduced feeling of heat on the skin and less irritation of the areas on which the product is applied. Additionally, incorporating a thickener may provide viscosity preparation the preparation in order to facilitate its sticking to the face and a better use thereof. | 2012-06-28 |
20120164097 | PREVENTION OF BODY ODOUR - Bad odors on textile materials are often caused by body odor. The invention relates to a textile material treatment method for inhibiting body odor on textile materials, by which means the treated textiles, after having been worn, even after sweat-inducing sports activities, have a significantly reduced bad odor or even no odor. The invention also relates to a perfume composition and to a textile material treatment agent, respectively comprising urea derivatives and/or phenacylthiazolium salts, that counteract the formation of body odor. | 2012-06-28 |
20120164098 | CROSSED-LINKED HYALURONIC ACID AND COLLAGEN AND USES THEREOF - The present invention discloses a cross-linked hyaluronic acid/collagen formulation which has improved composition for dermal filling and higher persistence than cross-linked collagen or HA alone. Also disclosed are methods for preparing cross-linked hyaluronic acid/collagen formulations and using such for augmenting soft tissues in mammals. | 2012-06-28 |
20120164099 | USE OF HUMAN PROSTATE CELL LINES IN CANCER TREATMENT - This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the mammal or human afflicted with cancer to mount an attack against the tumour lesion. In particular, the invention pertains to the use of whole-cells, derivatives and portions thereof with or without vaccine adjuvants and/or other accessory factors. More particularly, this disclosure describes the use of particular combinations of whole-cells and derivatives and portions thereof that form the basis of treatment strategy. | 2012-06-28 |
20120164100 | TEMPERATURE SENSITIVE HYDROGEL AND BLOCK COPOLYMERS - The present disclosure provides temperature sensitive hydrogels and block copolymers, processes for the production thereof, and therapeutic and research compositions employing these copolymers. | 2012-06-28 |
20120164101 | GM-CSF AND INTERLEUKIN-21 CONJUGATES AND USES THEREOF IN THE MODULATION OF IMMUNE RESPONSE AND TREATMENT OF CANCER - A conjugate protein comprising a GM-CSF or fragment thereof linked to an IL-21 or fragment thereof is described. The conjugate protein has unexpected immune activating and tumoricidal properties and is useful in a variety of therapeutic applications. | 2012-06-28 |
20120164102 | SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF - The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description. | 2012-06-28 |
20120164103 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections - Compounds represented by formula I: | 2012-06-28 |
20120164104 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors - The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present invention, the methods may further comprise at least one immunosuppressant agent to treat viral infection and/or viral induced tumor to a subject in need of immunosuppressant agents. | 2012-06-28 |
20120164105 | CONSTRUCTION OF A QUADRUPLE ENTEROTOXIN-DEFICIENT MUTANT OF BACILLUS THURINGIENSIS - Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the | 2012-06-28 |
20120164106 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF - The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease. | 2012-06-28 |
20120164107 | CYCLIC DI-AMP INDUCTION OF TYPE I INTERFERON - Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant | 2012-06-28 |
20120164108 | VIRUS STRAINS - The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains. | 2012-06-28 |
20120164109 | NUTRITIONAL COMPOSITION COMPRISING BIFIDOBACTERIUM LONGUM STRAINS AND REDUCING FOOD ALLERGY SYMPTOMS, ESPECIALLY IN INFANTS AND CHILDREN - A complete nutritional composition comprising | 2012-06-28 |
20120164110 | DIFFERENTIALLY METHYLATED REGIONS OF REPROGRAMMED INDUCED PLURIPOTENT STEM CELLS, METHOD AND COMPOSITIONS THEREOF - Provided herein are differentially methylated regions (DMRs) of reprogrammed iPS cells (R-DMRs) and methods of use thereof. The invention provides methods for detecting and analyzing alterations in the methylation status of DMRs in iPS cells, somatic cells and embryonic stem (ES) cells as well as methods for reprogramming somatic cells to generate an iPS cell. | 2012-06-28 |
20120164111 | NOVEL POST-TRANSLATIONAL FIBRINOGEN VARIANTS - Provided are novel post-translationally modified variants of fibrinogen, in particular human fibrinogen, a method for producing and isolating said variants, as well as methods of using the variant, in particular in systemic and local/topical treatment and prophylaxis of excessive bleeding. | 2012-06-28 |
20120164112 | EXPANDING HEMATOPOIETIC STEM CELLS - A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 2012-06-28 |
20120164113 | ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF - Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells. | 2012-06-28 |
20120164114 | TREATMENT OF IMMUNE-RELATED DISEASES AND DISORDERS USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 2012-06-28 |
20120164115 | Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 2012-06-28 |
20120164116 | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular and a filler conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration. | 2012-06-28 |
20120164117 | METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF - A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype. | 2012-06-28 |
20120164118 | COCAL VESICULOVIRUS ENVELOPE PSEUDOTYPED RETROVIRAL VECTORS - Provided herein are Cocal vesiculovirus envelope pseudotyped retroviral vectors that exhibit high titers, broad species and cell-type tropism, and improved serum stability. Disclosed Cocal vesiculovirus envelope pseudotyped retroviral vectors may be suitably employed for gene therapy applications and, in particular, for the ex vivo and in vivo delivery of a gene of interest to a wide variety of target cells. | 2012-06-28 |
20120164119 | BACTERIOCIN-PRODUCING LACTOBACILLUS PENTOSUS AND THE USE THEREOF IN FOOD AND PHARMACEUTICAL COMPOSITIONS - The present invention relates to a selected strain of | 2012-06-28 |
20120164120 | NOVEL MONASCUSPURPURONES, PREPARATION PROCESS THEREOF, AND USES OF THE MONASCUSPURPURONES - The present invention relates to a novel monascuspurpurone compound of formula (I): | 2012-06-28 |
20120164121 | ACTIVE INGREDIENT THAT IS OBTAINED FROM CANDIDA SAITOANA AND COSMETIC USE FOR DETOXIFYING SKIN CELLS - The object of the invention is the use of | 2012-06-28 |
20120164122 | PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF NEURODEGENERATIVE DISEASES - Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological heath and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotections mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. | 2012-06-28 |
20120164123 | METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN - Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide. Methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a modified polypeptide (such as HNP-1) including at least one ornithine residue in place of an arginine residue are also disclosed. | 2012-06-28 |
20120164124 | PHAGE-ASSOCIATED LYTIC ENZYMES FOR TREATMENT OF BACILLUS ANTHRACIS AND RELATED CONDITIONS - The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of | 2012-06-28 |
20120164125 | NUCLEIC ACID CLEAVING AGENT - A nucleic acid cleaving agent having a cleaving activity specific to a desired cleavage site in a nucleic acid such as large DNA, which comprises (1) a nucleic acid cleaving moiety, and (2) at least two zinc finger proteins bound to the nucleic acid cleaving moiety, wherein at least one of the zinc finger proteins can specifically bind to a nucleotide sequence located upstream from the target cleavage site, and at least one of the remaining zinc finger proteins can specifically bind to a nucleotide sequence located downstream from the target cleavage site. | 2012-06-28 |
20120164126 | PROTEINS FOR USE IN HUMAN AND ANIMAL STAPHYOCOCCUS INFECTIONS - The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci. | 2012-06-28 |
20120164127 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 2012-06-28 |
20120164128 | MEANS AND METHODS FOR COUNTERACTING POLYQ EXPANSION DISORDERS - The present invention provides means and methods for counteracting and/or preventing aggregation of a polyQ protein. Further provided are improved poly constructs which are, amongst other things, useful for testing assays. According to the invention, several peptidases like, e.g. tripeptidyl peptidase II (TPPII), appear to be capable of cleaving long polyQ peptides comprising at least 45 glutamine residues. Hence, according to the invention, administration of such peptidases to an individual suffering from a polyQ expansion disorder results in degradation of long polyQ peptides. | 2012-06-28 |
20120164129 | EXPRESSION OF THROMBIN VARIANTS - One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition. | 2012-06-28 |
20120164130 | Modified Factor IX Polypeptides and Uses Thereof - The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more amino acid substitutions. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B. | 2012-06-28 |
20120164131 | MODIFIED MUTANT COLLAGENASE AND IT'S USE IN FAT MELTING AND IN SCAR REDUCTION | 2012-06-28 |
20120164132 | Anticancer and immunomodulating molecules and fractions containing said molecules, and process for preparing said fractions and said molecules from fermented vegetal material, and their uses - Biologically active substances and fractions of wheat germ ferment/fermented wheat germ extract (FWGE), including formulation A250, the processes for their production, the pharmaceutical preparations containing them, and their uses. | 2012-06-28 |
20120164133 | METHODS OF IDENTIFYING AN ORGANISM - This disclosure features methods of identifying an organism. The methods include: (a) obtaining a nucleic acid sample from an organism; (b) imaging said nucleic acid; (c) obtaining a restriction map of said nucleic acid; and (d) correlating the restriction map of said nucleic acid with a restriction map database, thereby identifying the organism. | 2012-06-28 |
20120164134 | SUGAR-FREE CHEWABLE SUPPLEMENT - A sugar-free chewable composition for delivering dietary supplements and pharmaceutical compounds. The chewable composition includes a sugar-free delivery vehicle and an active ingredient. The delivery vehicle may include a sugar-free gummy candy. The active ingredient may include an over-the-counter drug or a prescription drug to provide a desired effect on the user. The active ingredient may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, amino acids, probiotics, prebiotics, and digestive enzymes. | 2012-06-28 |
20120164135 | METHOD FOR PREPARING COMPREHENSIVE ANTI-SURFACE ANTIBODY USING MICROORGANISM IMMOBILIZED AS ANTIGEN WITH PROTEIN CROSSLINKING AND IMMOBILIZATION REAGENT - A method for preparing comprehensive antibodies against whole proteins that are expressed on the surface of a microorganism and the comprehensive antibodies obtained by the method are provided. The method for preparing comprehensive antibodies against whole proteins that are expressed on the surface of a microorganism comprises:
| 2012-06-28 |
20120164136 | Compositions and Methods for Treatment of Cancer by Disrupting the LH/LHR Signaling Pathway - The present invention discloses compositions and methods for treating diseases such as cancer by targeting luteinizing hormone (LH) or its receptor (LHR) involved in androgen synthesis or testosterone production. | 2012-06-28 |
20120164137 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY GLYCOFORMS - The invention provides anti-FRA antibodies with novel N-linked neutral glycan profiles in that the relative amounts of one or more neutral glycans are increased or decreased compared to anti-FRA antibodies produced under reference cell culture conditions. The invention further provides anti-FRA antibodies with altered binding to FRA, altered antibody-dependent cellular cytotoxicity (ADCC) and/or altered rate and/or efficiency of internalization in a cell expressing FRA. In related aspects, the invention provides cell cultures comprising an anti-FRA antibody of the invention, a cell isolated from such a culture, kits and compositions comprising an anti-FRA antibody of the invention, methods of producing an anti-FRA antibody of the invention and diagnostic and therapeutic uses of an anti-FRA antibody of the invention. | 2012-06-28 |
20120164138 | USE OF ANTI-CD1 ANTIBODIES FOR THE MODULATION OF IMMUNE RESPONSES - The invention provides methods for the administration of an anti-CD1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer. | 2012-06-28 |
20120164139 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders - Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. | 2012-06-28 |
20120164140 | HEMOJUVELIN FUSION PROTEINS AND USES THEREOF - The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof. | 2012-06-28 |
20120164141 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS - The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable of penetrating cell membranes. Contacting various breast cancer cell lines with these molecule caused detachment, rounding, apoptosis and cell death. These effects were not observed in normal (non-cancerous) breast cells. | 2012-06-28 |
20120164142 | COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF - The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone. | 2012-06-28 |
20120164143 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) - Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 2012-06-28 |
20120164144 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 2012-06-28 |
20120164145 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE - , one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a α1,6-glucan-containing | 2012-06-28 |
20120164146 | ISOLATED MONOPHOSPHORYLATED PEPTIDE DERIVED FROM HUMAN ALPHA-ENOLASE USEFUL FOR DIAGNOSIS AND TREATMENT OF PANCREATIC ADENOCARCINOMA, ANTIBODIES DIRECTED AGAINST THE SAID MONOPHOSPHORYLATED PEPTIDE, AND USES THEREOF - An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma. | 2012-06-28 |
20120164147 | MAMMALIAN GENES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 2012-06-28 |
20120164148 | Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer - The present invention features compositions and methods for treating cancers such as melanoma, which have a subpopulation of self-renewing JARIDIB-positive cells essential to maintenance and metastatic progression of the cancer. | 2012-06-28 |
20120164149 | USE OF INHIBITORS OF LEUKOTRIENE B4 RECEPTOR BLT2 FOR TREATING ASTHMA - The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors. | 2012-06-28 |
20120164150 | Monoclonal Antibodies Against Activated Protein C - The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies. | 2012-06-28 |
20120164151 | Methods for Treatment of Muscular Dystrophy - The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided. | 2012-06-28 |
20120164152 | ANTI-IL-17F ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2012-06-28 |
20120164153 | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS - We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo. | 2012-06-28 |
20120164154 | METHOD FOR INCREASING INSULIN SENSITIVITY AND FOR TREATING AND PREVENTING TYPE 2 DIABETES - It is disclosed here that insulin sensitivity in a human or non-human animal can be increased by reducing stearoyl-CoA desaturase-1 (SCD1) activity in the animal. This provides a new tool for treating and preventing type 2 diabetes. Also disclosed are methods for identifying agents that can increase insulin sensitivity in a human or non-human animal through determining the agents' effects on SCD1 activity. | 2012-06-28 |
20120164155 | CHIMERIC MOLECULES - The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal α-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp 120. Soluble and membrane bound forms of trimeric and higher oligomeric forms of the chimeric proteins are provided as well as nucleic acid molecules encoding and expressing same, viral-like particles comprising same, compositions including pharmaceutical compositions, host cells and kits. Methods are described for producing immune responses including antibodies determined by the chimeric protein or VLP, as well as methods of screening using the chimeric protein, VLP and/or antibodies. | 2012-06-28 |
20120164156 | Recombinant F1-V Plague Vaccine - Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of | 2012-06-28 |
20120164157 | METHOD OF TREATING STROKE WITH THROMBOLYTIC AGENT - A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus. Also described are kits for carrying out this method. | 2012-06-28 |
20120164158 | Anti-ADDL Monoclonal Antibody and Use Thereof - The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42. | 2012-06-28 |
20120164159 | Humanised Antibodies to Toll-Like Receptor 2 and Uses Thereof - A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling. | 2012-06-28 |
20120164160 | MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. | 2012-06-28 |
20120164161 | Antibodies and Uses Thereof - The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields. | 2012-06-28 |
20120164162 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES - A method for the manufacture of products by biotechnological methods in bacterial cell culture is disclosed as well as products obtained, the use of certain additives to the media used in the manufacture of said products in bacterial cell culture media, and the use of said additives in reducing the detrimental effects of radicals in the manufacture of the products, as well as aspects related to these invention embodiments. The manufacturing process or method comprises adding one or more radical scavenging and/or antioxidative additive preferably selected from the group consisting of sterically hindered nitroxyls, sterically hindered hydroxylamines, sterically hindered hydroxylamine salt compounds, sterically hindered amino compounds and sterically hindered N-hydrocarbyloxyamines, benzofuranone compounds, as obligatory component(s) to the medium used during biosynthesis. | 2012-06-28 |
20120164163 | CDC45L PEPTIDES AND VACCINES INCLUDING THE SAME - The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer. | 2012-06-28 |
20120164164 | MULTIMERIC POLYPEPTIDES OF HLA-G INCLUDING ALPHA1-ALPHA3 MONOMERS AND PHARMACEUTICAL USES THEREOF - Multimeric polypeptides and pharmaceutical uses thereof; multimers comprising alpha3 and alpha1 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. Said multimers comprise at least two monomers, each of said monomers being selected in the group consisting of a peptide P2 of formula P1-X3 or X2-X3, wherein P1 is of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha1 domain (or alpha1 peptide) of HLA-G and X3 represents an alpha3 domain of HLA-G. | 2012-06-28 |
20120164165 | ZONA PELLUCIDA BINDING PEPTIDES, EXPRESSION VECTORS, COMPOSITIONS, AND METHODS FOR SPECIES-SPECIFIC IMMUNOCONTRACEPTION OF ANIMALS - Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines. | 2012-06-28 |
20120164166 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2012-06-28 |
20120164167 | SUB-REGION OF A PLASMODIUM PROTEIN WITH IMPROVED VACCINE POTENTIAL, AND MEDICAL USES THEREOF - The present application relates to a sub-region of a | 2012-06-28 |
20120164168 | B7-DC VARIANTS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided. | 2012-06-28 |
20120164169 | BOVINE HERPESVIRUS VACCINE - The present invention relates to mutant Bovine Herpesvirus 4 genomes, mutant Bovine Herpesvirus 4 viruses, to mutant Bovine Herpesvirus 4 genomes and viruses carrying a heterologous DNA sequence, cells transfected with mutant Bovine Herpesvirus 4 genomes, cells infected with mutant Bovine Herpesvirus 4 viruses, vaccines and carrier vaccines comprising such mutant Bovine Herpesvirus 4 viruses, methods for the preparation of such mutant Bovine Herpesvirus 4 genomes and such mutant Bovine Herpesvirus 4 viruses and to diagnostic test kits. | 2012-06-28 |
20120164170 | Porcine Circovirus Type 2 (PCV2), Immunogenic Composition Containing the Same, Test Kit, and Application Thereof - The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain. | 2012-06-28 |
20120164171 | Antiviral Activity of Bovine Type III Interferon Against Foot-and-Mouth Disease Virus - Interferons are the first line of defense against viral infections and administration of interferons as biotherapeutics has been demonstrated to be effective in controlling several viral infections. Here we report for the first time the identification and characterization of a member of the bovine type III IFN family, boIFN-λ3. We have expressed boIFN-λ3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Furthermore, we have tested the efficacy of boIFN-λ3 against FMDV in vivo by inoculation of cattle with Ad5-boIFN-λ3 followed by intradermolingual or aerosol virus challenge. Our results demonstrate that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-λ3 alone or in combination with IFN-α is able to confer delayed and reduced severity of FMD. Furthermore inoculation with Ad5-boIFN-λ3 alone conferred full protection against aerosol challenge for at least 7 days after administration suggesting that type III IFN used in combination with FMD vaccines could fill one of the current gaps in emergency vaccination against FMDV. | 2012-06-28 |
20120164172 | Cancer Therapy - An agent that stimulates antiviral immunity may be used, for the treatment of cancer. A product comprising an immunostimulant and a vector comprising a transgene that promotes death of neoplastic cells, may also be used for simultaneous, sequential or separate administration in the treatment of cancer. | 2012-06-28 |
20120164173 | Papilloma Pseudovirus and Preparation - The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body. | 2012-06-28 |
20120164174 | ADJUVANT COMPOSITION CONTAINING POLY-GAMMA-GLUTAMIC ACID-CHITOSAN NANOPARTICLES - The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies. | 2012-06-28 |
20120164175 | NOVEL INFLUENZA VIRUS - The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. | 2012-06-28 |
20120164176 | RSV F PROTEIN COMPOSITIONS AMD METHODS FOR MAKING SAME - The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F. | 2012-06-28 |
20120164177 | RHINOVIRUS VACCINES - The present invention relates generally to peptide vaccines. More specifically, the present invention relates to vaccines against rhinoviruses and other related and non-related pathogenic animal viruses. In addition, the present invention relates generally to methods of designing and producing vaccines against viruses and, in certain embodiments, against rhinoviruses and other pathogenic viruses. | 2012-06-28 |
20120164178 | Vaccine - The present invention provides an immunogenic composition comprising a | 2012-06-28 |
20120164179 | Leishmania Challenge Model - The present invention provides a method for effectively and reproducibly infecting canines with | 2012-06-28 |
20120164180 | Cancer Vaccines and Therapeutic Methods - Compositions and methods of producing improved cancer vaccines are described. In addition, methods of identifying tumor associated antigens are also described. | 2012-06-28 |
20120164181 | Non-Specific Immunostimulating Agents - The present invention includes a lipid vesicle. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof. | 2012-06-28 |
20120164182 | Botulinum nanoemulsions - The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision. | 2012-06-28 |